transcranial magnetic stimulation for Parkinson's (PRESS-PD, NCT06383247)
Reduce slowness stiffness and instability
- Trial ID
- NCT06383247
- Official Title
- A Randomized, Double-blind, Multicenter, Placebo-controlled Trial (PRESS-PD)
- Study Acronym
- PRESS-PD
- Goal
- Reduce slowness stiffness and instability
- Phase
- NA
- Status
- RECRUITING
- Sponsor
- Anhui Medical University
- Study Type
- INTERVENTIONAL
- Enrollment
- 290 participants
- Conditions
- Parkinson Disease, Transcranial Magenetic Stimualtion, Supplementary Motor Area
- Interventions
- transcranial magnetic stimulation
Summary For Families
PRESS-PD is testing whether focused magnetic stimulation of the brain's supplementary motor area can ease core motor problems in Parkinson's, like slowness, stiffness, and unstable motor control. It uses repetitive transcranial magnetic stimulation, a noninvasive device that delivers magnetic pulses to change cortical excitability and strengthen motor circuit connections, and because it is not a drug it does not chemically interact with levodopa while participants keep stable medication doses. The trial is enrolling adults 40 and older with idiopathic Parkinson's, MDS-UPDRS part III score of at least 8, Hoehn‑Yahr stage 1 to 4, MMSE ≥22, stable meds for 4 weeks, and no epilepsy, metal implants, deep brain stimulation, major brain injury, or recent trial participation.
Locations
- Cognitive Neuropsychology Lab Anhui Medical University, Hefei, Anhui, China
Frequently Asked Questions
- What is this trial testing?
- This trial is studying transcranial magnetic stimulation. PRESS-PD is testing whether focused magnetic stimulation of the brain's supplementary motor area can ease core motor problems in Parkinson's, like slowness, stiffness, and unstable motor control. It uses repetitive transcranial magnetic stimulation, a noninvasive device that delivers magnetic pulses to change cortical excitability and strengthen motor circuit connections, and because it is not a drug it does not chemically interact with levodopa while participants keep stable medication doses. The trial is enrolling adults 40 and older with idiopathic Parkinson's, MDS-UPDRS part III score of at least 8, Hoehn‑Yahr stage 1 to 4, MMSE ≥22, stable meds for 4 weeks, and no epilepsy, metal implants, deep brain stimulation, major brain injury, or recent trial participation.
- Who can participate?
- Participants must be at least 40 Years.
- Where is this trial located?
- This trial is recruiting at 1 location.
- Does it cost anything to join?
- You are never charged a fee to join a legitimate clinical trial, and the study treatment and study-specific tests are provided by the trial sponsor at no charge. In the US, routine care you would receive anyway can still be billed to you or your insurance; coverage rules differ by country, and trials in the UK and Canada usually run through public health systems. Travel, parking, and time are real costs, and some trials reimburse them while others do not. Before enrolling, ask the study coordinator to explain in writing what is and is not covered.
- How long does the trial last?
- This trial is estimated to last approximately 2 years and 1 month.
- Can I leave the trial if I change my mind?
- Yes. You can withdraw from any clinical trial at any time, for any reason, without affecting your standard medical care. Trials are voluntary by law. The team may ask if you are willing to do a brief exit visit so they can collect safety information, but you are not obligated.
- Can my spouse or care partner come with me to visits?
- In most cases yes, and it is often encouraged. Care partners can help with notes, questions, and getting home safely after a long visit. Some study assessments do need to happen one on one, but care partners are usually welcome for the rest of the appointment.
- Will I get a placebo in this trial?
- This trial has 2 groups, and 1 is a placebo group. Because assignment is random, you have about a 1 in 2 chance (roughly 50%) of being in the placebo group, assuming the groups are filled equally. Ask the coordinator to confirm the exact assignment ratio.
- How many visits does this trial involve?
- Daily sessions for 1 week.